Clinical trial
Randomised, Controlled Study Comparing Chemotherapy Plus Intercalated EGFR-Tyrosine Kinase Inhibitors Combination Therapy With EGFR-Tyrosine Kinase Inhibitors Alone Therapy as First-line Treatment for Patients With Non-Small-Cell Lung Cancer
NCT02031601 is registered in ClinicalTrials.gov with Qilu Hospital of Shandong University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Randomised, Controlled Study Comparing Chemotherapy Plus Intercalated EGFR-Tyrosine Kinase Inhibitors Combination Therapy With EGFR-Tyrosine Kinase Inhibitors Alone Therapy as First-line Treatment for Patients With Non-Small-Cell Lung Cancer
- Lead sponsor
- Qilu Hospital of Shandong University
- Phase
- Phase 4
- Overall status
- Unknown status
- Start date
- January 31, 2014
- Completion date
- December 31, 2017
- Enrollment
- 250 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
non-small-cell lung cancer